Fate Therapeutics Inc (FATE)

4.10
0.17 4.30
NASDAQ : Health Care
Prev Close 3.93
Open 4.18
Day Low/High 4.00 / 4.24
52 Wk Low/High 1.46 / 8.05
Volume 254.16K
Avg Volume 197.80K
Exchange NASDAQ
Shares Outstanding 41.39M
Market Cap 162.65M
EPS -1.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

3 Small Biotechs With Insider Buying

3 Small Biotechs With Insider Buying

Insiders have an edge in this complex sector, so it's worth checking them out.

On the Hunt for Holiday Movers

On the Hunt for Holiday Movers

I'm still bullish, but I'm looking over my shoulder to see if there are some bears sneaking up.

Rotation Is the Name of the Game

Rotation Is the Name of the Game

Traders are also looking for smaller-caps that can move big around the holiday.

Shark Bites: These Steel Names Are Looking Strong

Shark Bites: These Steel Names Are Looking Strong

A few plays on this holiday trading.

Fate Therapeutics Announces Oral Presentation On Natural Killer Cell Product Candidate FATE-NK100 At The 2016 ASH Annual Meeting

Fate Therapeutics Announces Oral Presentation On Natural Killer Cell Product Candidate FATE-NK100 At The 2016 ASH Annual Meeting

Five Additional Presentations to Highlight the Company's Cellular Immunotherapy Programs

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: CTRN, FSFG, LWAY Downgrades: BAM, BT, DHT, RFIL, SNP Initiations: FATE Read on to get TheStreet Quant Ratings' detailed report:

Fate Therapeutics Announces FDA Fast Track Designation For ProTmune™

Fate Therapeutics Announces FDA Fast Track Designation For ProTmune™

Phase 1/2 Clinical Trial of ProTmune for Prevention of Acute GvHD and CMV Infection Now Open for Enrollment

5 Stocks Poised for Big Breakouts

5 Stocks Poised for Big Breakouts

These stocks look ready to break out and trade higher from current levels.

TheStreet Quant Rating: D (Sell)